drugset / Trial / NCT00537498
Urokinase Therapy in Diabetic Foot Syndrome
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate whether a treatment with urokinase (500 000 or 1 000 000 IU) can lead to ulcer-healing, lower rate of major amputation, and prolonged survival in patients with diabetic foot syndrome.
Timeline
- Start
- 2002-02
- Primary completion
- —
- Completion
- 2006-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Urokinase | Protein / enzyme biologic | 500000 iu | Intravenous |
| Subject | Urokinase | Protein / enzyme biologic | 1e+06 iu | Intravenous |